Title | The matrikine acetyl-proline-glycine-proline and clinical features of COPD: findings from SPIROMICS. |
Publication Type | Publication |
Year | 2019 |
Authors | J Wells M, Xing D, Viera L, Burkes RM, Wu Y, Bhatt SP, Dransfield MT, Couper DJ, O'Neal W, Hoffman EA, Gaggar A, Barjaktarevic I, Curtis JL, Labaki WW, Han MLan K, Freeman CM, Putcha N, Schlange T, J Blalock E |
Corporate Authors | SPIROMICS Investigators, |
Journal | Respir Res |
Volume | 20 |
Issue | 1 |
Pagination | 254 |
Date Published | 2019 Nov 12 |
ISSN | 1465-993X |
Keywords | Aged, biomarkers, Cohort Studies, Female, Glycine, Humans, Male, Middle Aged, Proline, Prospective Studies, Pulmonary Disease, Chronic Obstructive, Spirometry, Sputum |
Abstract | BACKGROUND: Pulmonary and systemic inflammation are central features of chronic obstructive pulmonary disease (COPD). Previous studies have demonstrated relationships between biologically active extracellular matrix components, or matrikines, and COPD pathogenesis. We studied the relationships between the matrikine acetyl-proline-glycine-proline (AcPGP) in sputum and plasma and clinical features of COPD.METHODS: Sputum and plasma samples were obtained from COPD participants in the SPIROMICS cohort at enrollment. AcPGP was isolated using solid phase extraction and measured by mass spectrometry. Demographics, spirometry, quality of life questionnaires, and quantitative computed tomography (CT) imaging with parametric response mapping (PRM) were obtained at baseline. Severe COPD exacerbations were recorded at 1-year of prospective follow-up. We used linear and logistic regression models to measure associations between AcPGP and features of COPD, and Kaplan-Meier analyses to measure time-to-first severe exacerbation.RESULTS: The 182 COPD participants in the analysis were 66 ± 8 years old, 62% male, 84% White race, and 39% were current smokers. AcPGP concentrations were 0.61 ± 1.89 ng/mL (mean ± SD) in sputum and 0.60 ± 1.13 ng/mL in plasma. In adjusted linear regression models, sputum AcPGP was associated with FEV/FVC, spirometric GOLD stage, PRM-small airways disease, and PRM-emphysema. Sputum AcPGP also correlated with severe AECOPD, and elevated sputum AcPGP was associated with shorter time-to-first severe COPD exacerbation. In contrast, plasma AcPGP was not associated with symptoms, pulmonary function, or severe exacerbation risk.CONCLUSIONS: In COPD, sputum but not plasma AcPGP concentrations are associated with the severity of airflow limitation, small airways disease, emphysema, and risk for severe AECOPD at 1-year of follow-up.TRIAL REGISTRATION: ClinicalTrials.gov: NCT01969344 (SPIROMICS). |
DOI | 10.1186/s12931-019-1230-8 |
Alternate Journal | Respir Res |
PubMed ID | 31718676 |
PubMed Central ID | PMC6852714 |
Grant List | U24 HL141762 / HL / NHLBI NIH HHS / United States S10 OD018526 / OD / NIH HHS / United States P30 ES005605 / ES / NIEHS NIH HHS / United States K24 HL140108 / HL / NHLBI NIH HHS / United States K08 HL123940 / HL / NHLBI NIH HHS / United States I01 CX000911 / CX / CSRD VA / United States R01 HL102371 / HL / NHLBI NIH HHS / United States K24 HL137013 / HL / NHLBI NIH HHS / United States U01 HL137880 / HL / NHLBI NIH HHS / United States R35 HL135710 / HL / NHLBI NIH HHS / United States P30 DK054759 / DK / NIDDK NIH HHS / United States |
The matrikine acetyl-proline-glycine-proline and clinical features of COPD: findings from SPIROMICS.
MS#:
MS198
Manuscript Full Title:
The matrikine acetyl-proline-glycine-proline and clinical features of COPD: findings from SPIROMICS.
ECI:
Manuscript Status:
Published and Public